Moulavasilis joined M42 in April 2023 and was appointed Group CEO in May 2025. The company has more than 480 facilities in 27 countries across 18 subsidiaries including Cleveland Clinic Abu Dhabi, and Diaverum that conducts 6.5 million dialysis treatments globally per year. In June 2025, M42 partnered with AstraZeneca and SOPHiA GENETICS to launch advanced liquid biopsy testing in the U.A.E. for faster, non-invasive cancer diagnostics. In July 2025, it collaborated with GE Healthcare to advance AI-powered healthcare solutions. Moulavasilis previously served as Group CEO of Affidea and earlier held senior roles at GE Healthcare.